Morgan Stanley
KZIA

Morgan Stanley’s Kazia Therapeutics KZIA Stock Holding History

Morgan Stanley’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.44K Hold
1,000
– – ﹤0.01% 7032
2025
Q4 		$6.89K Buy
1,000
+800
+400% +$6.82K ﹤0.01% 6983
2025
Q3 		$1.44K Buy
+200
New +$1.66K ﹤0.01% 7356
2025
Q1 		– Sell
-4,688
Closed -$41.5K – 8166
2024
Q4 		$41.5K Buy
4,688
+283
+6% +$6.54K ﹤0.01% 6346
2024
Q3 		$94.7K Buy
4,405
+383
+10% +$7.64K ﹤0.01% 6029
2024
Q2 		$46K Buy
4,022
+65
+2% +$966 ﹤0.01% 6204
2024
Q1 		$61.3K Sell
3,957
-4,105
-51% -$61.5K ﹤0.01% 6141
2023
Q4 		$177K Buy
8,062
+4,263
+112% +$125K ﹤0.01% 5991
2023
Q3 		$189K Sell
3,799
-292
-7% -$14.3K ﹤0.01% 5603
2023
Q2 		$237K Buy
4,091
+102
+3% +$6.43K ﹤0.01% 5574
2023
Q1 		$205K Sell
3,989
-1,158
-22% -$55.6K ﹤0.01% 5698
2022
Q4 		$158K Buy
5,147
+1,058
+26% +$39.8K ﹤0.01% 5764
2022
Q3 		$224K Buy
4,089
+57
+1% +$6.37K ﹤0.01% 5683
2022
Q2 		$846K Sell
4,032
-1,836
-31% -$564K ﹤0.01% 5118
2022
Q1 		$2.26M Sell
5,868
-121
-2% -$43.2K ﹤0.01% 4422
2021
Q4 		$2.52M Buy
5,989
+242
+4% +$121K ﹤0.01% 4395
2021
Q3 		$3.25M Buy
5,747
+1,068
+23% +$525K ﹤0.01% 4147
2021
Q2 		$2.31M Buy
4,679
+63
+1% +$33.2K ﹤0.01% 4522
2021
Q1 		$2.86M Buy
4,616
+1,024
+29% +$535K ﹤0.01% 3972
2020
Q4 		$1.55M Buy
3,592
+574
+19% +$229K ﹤0.01% 4369
2020
Q3 		$1.02M Buy
3,018
+924
+44% +$260K ﹤0.01% 4204
2020
Q2 		$355K Buy
2,094
+508
+32% +$74.2K ﹤0.01% 4781
2020
Q1 		$230K Buy
1,586
+118
+8% +$23.4K ﹤0.01% 4804
2019
Q4 		$319K Buy
1,468
+128
+10% +$24.4K ﹤0.01% 5172
2019
Q3 		$251K Buy
1,340
+44
+3% +$6.02K ﹤0.01% 5019
2019
Q2 		$157K Buy
1,296
+36
+3% +$5.53K ﹤0.01% 5130
2019
Q1 		$210K Buy
1,260
+34
+3% +$5.6K ﹤0.01% 5039
2018
Q4 		$149K Buy
1,226
+21
+2% +$2.85K ﹤0.01% 5404
2018
Q3 		$192K Buy
1,205
+88
+8% +$15K ﹤0.01% 5471
2018
Q2 		$165K Buy
1,117
+117
+12% +$29.1K ﹤0.01% 5600
2018
Q1 		$281K Buy
1,000
+80
+9% +$18.5K ﹤0.01% 5319
2017
Q4 		$146K Buy
920
+130
+16% +$19.2K ﹤0.01% 5518
2017
Q3 		$119K Buy
790
+64
+9% +$10.2K ﹤0.01% 5529
2017
Q2 		$131K Buy
726
+89
+14% +$16.8K ﹤0.01% 5523
2017
Q1 		$172K Buy
637
+143
+29% +$45K ﹤0.01% 5390
2016
Q4 		$145K Buy
494
+175
+55% +$58.6K ﹤0.01% 5457
2016
Q3 		$124K Buy
319
+175
+122% +$68.2K ﹤0.01% 5221
2016
Q2 		$54K Buy
144
+111
+336% +$47.7K ﹤0.01% 5506
2016
Q1 		$16K Buy
33
+18
+120% +$7.59K ﹤0.01% 5999
2015
Q4 		$6K Hold
15
– – ﹤0.01% 6344
2015
Q3 		$7K Hold
15
– – ﹤0.01% 6328
2015
Q2 		$12K Buy
15
+1
+7% +$1.14K ﹤0.01% 6262
2015
Q1 		$12K Buy
14
+2
+17% +$1.15K ﹤0.01% 6182
2014
Q4 		$5K Hold
12
– – ﹤0.01% 6334
2014
Q3 		$7K Hold
12
– – ﹤0.01% 6264
2014
Q2 		$8K Sell
12
-9
-43% -$6.92K ﹤0.01% 6228
2014
Q1 		$17K Buy
21
+6
+40% +$5.11K ﹤0.01% 6001
2013
Q4 		$13K Buy
+15
New +$14.4K ﹤0.01% 5981

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Morgan Stanley's KZIA Position: Q1 2026 in Review

Morgan Stanley held its Kazia Therapeutics (KZIA) position steady in Q1 2026 at 1,000 shares worth $7.44K. The position accounts for ﹤0.01% of the portfolio, ranked #7032.

Morgan Stanley first reported a position in KZIA in Q4 2013 and has held it in 48 quarters since. The position peaked at $3.25M in Q3 2021. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Morgan Stanley held 1,000 shares of Kazia Therapeutics worth $7.44K as of Q1 2026.
  • Morgan Stanley left its Kazia Therapeutics share count unchanged in Q1 2026.
  • Kazia Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7032 holding.
  • Morgan Stanley first reported a position in Kazia Therapeutics in Q4 2013 and has held it in 48 quarters since.
  • Morgan Stanley's Kazia Therapeutics position peaked at $3.25M in Q3 2021.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.